Novel Fungal Infection Treatment to Be Presented
New findings for a potential invasive aspergillosis therapy will be shared at the upcoming IDWeek 2026 conference.
Updated on Oct. 6, 2026 in Asthma
Live Poll
Would you participate in a clinical trial for a life-threatening infection with limited treatment options?
Data from the Phase 3 OASIS trial regarding the investigational drug olorofim are set for presentation on October 22, 2026, at IDWeek in Washington, D.C. If eventually approved, this treatment would represent the first novel mechanism for invasive aspergillosis in over two decades.
Why it matters
Invasive aspergillosis is a serious condition characterized by limited treatment options due to rising drug resistance and medication toxicity. A new therapy could expand clinical options for patients currently facing challenges with existing standard-of-care treatments.
The Phase 3 OASIS trial enrolled 225 subjects between June 2018 and September 2022 to evaluate the efficacy of olorofim. The trial utilized a 2:1 randomization ratio to compare the investigational agent against AmBisome within a 20% non-inferiority margin.
The players
F2G Ltd.
A Manchester-based biotechnology company focused on the development of novel antifungal therapies for rare and serious diseases.
FDA
The United States regulatory agency responsible for evaluating the safety and efficacy of new drug applications and medical treatments.
The details
Olorofim is an investigational agent currently holding orphan drug, QIDP, and Breakthrough Therapy designations from the FDA. In Study 32, participants received an initial 150 mg oral loading dose, followed by 90 mg doses twice daily for 90 days. The trial results are designed to establish whether this novel mechanism can effectively manage fungal infections where current therapies have become limited by resistance.
Timeline
Enrollment for Study 32 occurred between June 2018 and September 2022.
IDWeek 2026 takes place October 21-24, 2026, in Washington, D.C.
The oral presentation of OASIS trial data is scheduled for October 22, 2026.
A poster session regarding quality of life outcomes is set for October 24, 2026.
Health Landscape
The pursuit of new antifungal agents reflects a shift in medical science toward addressing long-standing issues of drug resistance in fungal pathogens. Olorofim sits within the FDA Breakthrough Therapy designation program, aiming to modernize a treatment landscape that has seen few mechanism innovations in over 20 years.
This development is currently in the investigational phase and is not available for clinical use. Patients managing chronic or severe fungal conditions should discuss current treatment options and emerging research with their physician.
The takeaway
The clinical trial results highlight the ongoing effort to introduce new antifungal mechanisms for resistant infections. Readers interested in emerging clinical research can monitor official updates at IDWeek to track the progress of new, non-standard treatments.
Further reading
For context on the evolution of respiratory and fungal infection care, visit our Asthma section.
More information
View the complete Study 32 clinical trial details at the official registry.
Live Poll
Would you participate in a clinical trial for a life-threatening infection with limited treatment options?
